EFEK TERAPI ADJUVAN METFORMIN PADA KANKER KOLOREKTAL
Abstract
Kanker kolorektal adalah suatu keganasan yang terjadi pada kolon, rektum, atau keduanya. Angka kejadian kanker kolorektal menempati posisi ketiga dan menjadi penyebab kematian tersering kedua pada semua jenis kelamin. Pengobatan kanker kolorektal dengan agen kemoterapi tunggal, yaitu 5-fluorourasil atau kombinasi dengan oksaliplatin dan avastin dapat memberikan perbaikan penyakit, namun memberikan beberapa efek samping. Tujuan dari artikel ini yaitu untuk mengetahui mekanisme kerja obat metformin sebagai terapi adjuvan dalam menghambat pertumbuhan sel pada pasien kanker kolorektal. Metode yang digunakan oleh penulis dalam artikel ini adalah metode telaah pustaka, dengan mengumpulkan beberapa sumber tertulis melalui pencarian data yang di akses melalui Google scholar, Pubmed, Mendeley, dan Science direct. Hasil telaah pustaka menunjukkan bahwa terdapat beberapa mekanisme kerja obat metformin dalam menghambat proliferasi dan pertumbuhan sel, antara lain dengan aktivasi jalur AMPK, menurunkan jumlah insulin dan IGF, serta menurunkan ekspresi Inhibin βA (INHBA) yang pada akhirnya dapat menghambat mitosis sel. Simpulan dari telaah pustaka ini adalah metformin dapat dipilih menjadi terapi adjuvan dalam pengobatan kanker kolorektal karena banyaknya efek yang ditimbulkan dalam menghambat pertumbuhan sel kanker. Melalui telaah pustaka ini diharapkan metformin dapat dimanfaatkan sebagai terapi adjuvan pasien kanker kolorektal baik pada saat ini maupun di kemudian hari.
Kata kunci : kanker kolorektal, metformin, proliferasi sel
References
1. Kalyanaraman B. Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism. Vol. 12, Redox Biology. Elsevier B.V.; 2017. p. 833–42.
2. Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res [Internet]. 2019 [cited 2023 Apr 1];11:3295. Available from: /pmc/articles/PMC6497052/
3. GLOBOCAN 2020: New Global Cancer Data | UICC [Internet]. [cited 2023 Aug 24]. Available from: https://www.uicc.org/news/globocan-2020-new-global-cancer-data
4. Alzahrani SM, Al Doghaither HA, Al-Ghafar AB. General insight into cancer: An overview of colorectal cancer (review). Mol Clin Oncol. 2021 Dec 1;15(6).
5. Mármol I, Sánchez-de-Diego C, Dieste AP, Cerrada E, Yoldi MJR. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci [Internet]. 2017 Jan 19 [cited 2023 Apr 1];18(1). Available from: /pmc/articles/PMC5297828/
6. Knowlton CA, Mackay MK, Speer TW, Vera RB, Arthur DW, Wazer DE, et al. Colon Cancer. Encyclopedia of Radiation Oncology [Internet]. 2023 Jun 3 [cited 2023 Aug 24];77–77. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470380/
7. Duan B, Zhao Y, Bai J, Wang J, Duan X, Luo X, et al. Colorectal Cancer: An Overview. Gastrointestinal Cancers [Internet]. 2022 Sep 30 [cited 2023 Aug 25];1–12. Available from: https://www.ncbi.nlm.nih.gov/books/NBK586003/
8. Kamarudin MNA, Sarker MMR, Zhou JR, Parhar I. Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects. J Exp Clin Cancer Res [Internet]. 2019 Dec 12 [cited 2023 Apr 1];38(1). Available from: /pmc/articles/PMC6909457/
9. Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of gene–environment interactions on cancer development. Vol. 17, International Journal of Environmental Research and Public Health. MDPI AG; 2020. p. 1–15.
10. Yu GH, Li SF, Wei R, Jiang Z. Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications. Vol. 2022, Journal of Diabetes Research. Hindawi Limited; 2022.
11. Zi F, Zi H, Li Y, He J, Shi Q, Cai Z. Metformin and cancer: An existing drug for cancer prevention and therapy. Oncol Lett [Internet]. 2018 Jan 1 [cited 2023 Apr 1];15(1):683. Available from: /pmc/articles/PMC5772929/
12. Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Vol. 11, Frontiers in Endocrinology. Frontiers Media S.A.; 2020.
13. Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Vol. 12, Therapeutic Advances in Endocrinology and Metabolism. SAGE Publications Ltd; 2021.
14. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia [Internet]. 2017 Sep 1 [cited 2023 Apr 1];60(9):1577. Available from: /pmc/articles/PMC5552828/
15. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Vol. 2, Annals of Translational Medicine. AME Publishing Company; 2014.
16. Permatasari Indah P. View of The Role of Metformin as Therapy in Colorectal Cancer [Internet]. 2020 [cited 2023 Aug 16]. p. 1–5. Available from: https://www.journalofmedula.com/index.php/medula/article/view/70/31
17. Xiao Q, Xiao J, Liu J, Liu J, Shu G, Yin G. ARTICLE Metformin suppresses the growth of colorectal cancer by targeting INHBA to inhibit TGF-β/PI3K/AKT signaling transduction. [cited 2023 Aug 16]; Available from: https://doi.org/10.1038/s41419-022-04649-4
18. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008;99(11):2136–41.
19. Hua H, Kong Q, Yin J, Zhang J, Jiang Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: A challenge for cancer therapy. Vol. 13, Journal of Hematology and Oncology. BioMed Central Ltd.; 2020.
20. Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: Novel targeted therapies. Vol. 2015, BioMed Research International. Hindawi Limited; 2015.
21. J. Quinn B, Kitagawa H, M. Memmott R. Repositioning metformin for cancer prevention and treatment. Trends in Endocrinology & Metabolism. Cell Press [Internet]. 2013 Sep [cited 2023 Aug 16];24(9):469–80. Available from: https://sci-hub.se/10.1016/j.tem.2013.05.004
22. Rey V, Tamargo-Gómez I. From Kinases to Diseases: Investigating the Role of AMPK in Human Pathologies. Kinases and Phosphatases. 2023 Aug 1;1(3):181–205.
23. Galdieri L, Gatla H, Vancurova I, Vancura A. Activation of AMP-activated protein kinase by metformin induces protein acetylation in prostate and ovarian cancer cells. Journal of Biological Chemistry. 2016 Nov 25;291(48):25154–66.
24. LIU G jie, HU X, Jia Y, Huo B, Yang L, Liu F. Identification of INHBA as a Potential Biomarker for Gastric Cancer by Comprehensive Analysis. 2020.
25. Li X, Yu W, Liang C, Xu Y, Zhang M, Ding X, et al. INHBA is a prognostic predictor for patients with colon adenocarcinoma. BMC Cancer. 2020 Apr 15;20(1).
26. Peng S, Wang J, Zhang W, Li H, Xu L. INHBA knockdown inhibits proliferation and invasion of nasopharyngeal carcinoma SUNE1 cells in vitro [Internet]. Vol. 13, Int J Clin Exp Pathol. 2020. Available from: www.ijcep.com/
27. He Z, Liang J, Wang B. Inhibin, beta A regulates the transforming growth factor-beta pathway to promote malignant biological behaviour in colorectal cancer. Cell Biochem Funct [Internet]. 2021 Mar 1 [cited 2023 Aug 16];39(2):258–66. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cbf.3573
28. Namwanje M, Brown CW. Activins and inhibins: Roles in development, physiology, and disease. Cold Spring Harb Perspect Biol. 2016 Jul 1;8(7).
2. Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res [Internet]. 2019 [cited 2023 Apr 1];11:3295. Available from: /pmc/articles/PMC6497052/
3. GLOBOCAN 2020: New Global Cancer Data | UICC [Internet]. [cited 2023 Aug 24]. Available from: https://www.uicc.org/news/globocan-2020-new-global-cancer-data
4. Alzahrani SM, Al Doghaither HA, Al-Ghafar AB. General insight into cancer: An overview of colorectal cancer (review). Mol Clin Oncol. 2021 Dec 1;15(6).
5. Mármol I, Sánchez-de-Diego C, Dieste AP, Cerrada E, Yoldi MJR. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci [Internet]. 2017 Jan 19 [cited 2023 Apr 1];18(1). Available from: /pmc/articles/PMC5297828/
6. Knowlton CA, Mackay MK, Speer TW, Vera RB, Arthur DW, Wazer DE, et al. Colon Cancer. Encyclopedia of Radiation Oncology [Internet]. 2023 Jun 3 [cited 2023 Aug 24];77–77. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470380/
7. Duan B, Zhao Y, Bai J, Wang J, Duan X, Luo X, et al. Colorectal Cancer: An Overview. Gastrointestinal Cancers [Internet]. 2022 Sep 30 [cited 2023 Aug 25];1–12. Available from: https://www.ncbi.nlm.nih.gov/books/NBK586003/
8. Kamarudin MNA, Sarker MMR, Zhou JR, Parhar I. Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects. J Exp Clin Cancer Res [Internet]. 2019 Dec 12 [cited 2023 Apr 1];38(1). Available from: /pmc/articles/PMC6909457/
9. Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of gene–environment interactions on cancer development. Vol. 17, International Journal of Environmental Research and Public Health. MDPI AG; 2020. p. 1–15.
10. Yu GH, Li SF, Wei R, Jiang Z. Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications. Vol. 2022, Journal of Diabetes Research. Hindawi Limited; 2022.
11. Zi F, Zi H, Li Y, He J, Shi Q, Cai Z. Metformin and cancer: An existing drug for cancer prevention and therapy. Oncol Lett [Internet]. 2018 Jan 1 [cited 2023 Apr 1];15(1):683. Available from: /pmc/articles/PMC5772929/
12. Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Vol. 11, Frontiers in Endocrinology. Frontiers Media S.A.; 2020.
13. Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Vol. 12, Therapeutic Advances in Endocrinology and Metabolism. SAGE Publications Ltd; 2021.
14. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia [Internet]. 2017 Sep 1 [cited 2023 Apr 1];60(9):1577. Available from: /pmc/articles/PMC5552828/
15. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Vol. 2, Annals of Translational Medicine. AME Publishing Company; 2014.
16. Permatasari Indah P. View of The Role of Metformin as Therapy in Colorectal Cancer [Internet]. 2020 [cited 2023 Aug 16]. p. 1–5. Available from: https://www.journalofmedula.com/index.php/medula/article/view/70/31
17. Xiao Q, Xiao J, Liu J, Liu J, Shu G, Yin G. ARTICLE Metformin suppresses the growth of colorectal cancer by targeting INHBA to inhibit TGF-β/PI3K/AKT signaling transduction. [cited 2023 Aug 16]; Available from: https://doi.org/10.1038/s41419-022-04649-4
18. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008;99(11):2136–41.
19. Hua H, Kong Q, Yin J, Zhang J, Jiang Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: A challenge for cancer therapy. Vol. 13, Journal of Hematology and Oncology. BioMed Central Ltd.; 2020.
20. Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: Novel targeted therapies. Vol. 2015, BioMed Research International. Hindawi Limited; 2015.
21. J. Quinn B, Kitagawa H, M. Memmott R. Repositioning metformin for cancer prevention and treatment. Trends in Endocrinology & Metabolism. Cell Press [Internet]. 2013 Sep [cited 2023 Aug 16];24(9):469–80. Available from: https://sci-hub.se/10.1016/j.tem.2013.05.004
22. Rey V, Tamargo-Gómez I. From Kinases to Diseases: Investigating the Role of AMPK in Human Pathologies. Kinases and Phosphatases. 2023 Aug 1;1(3):181–205.
23. Galdieri L, Gatla H, Vancurova I, Vancura A. Activation of AMP-activated protein kinase by metformin induces protein acetylation in prostate and ovarian cancer cells. Journal of Biological Chemistry. 2016 Nov 25;291(48):25154–66.
24. LIU G jie, HU X, Jia Y, Huo B, Yang L, Liu F. Identification of INHBA as a Potential Biomarker for Gastric Cancer by Comprehensive Analysis. 2020.
25. Li X, Yu W, Liang C, Xu Y, Zhang M, Ding X, et al. INHBA is a prognostic predictor for patients with colon adenocarcinoma. BMC Cancer. 2020 Apr 15;20(1).
26. Peng S, Wang J, Zhang W, Li H, Xu L. INHBA knockdown inhibits proliferation and invasion of nasopharyngeal carcinoma SUNE1 cells in vitro [Internet]. Vol. 13, Int J Clin Exp Pathol. 2020. Available from: www.ijcep.com/
27. He Z, Liang J, Wang B. Inhibin, beta A regulates the transforming growth factor-beta pathway to promote malignant biological behaviour in colorectal cancer. Cell Biochem Funct [Internet]. 2021 Mar 1 [cited 2023 Aug 16];39(2):258–66. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cbf.3573
28. Namwanje M, Brown CW. Activins and inhibins: Roles in development, physiology, and disease. Cold Spring Harb Perspect Biol. 2016 Jul 1;8(7).
Published
2024-12-31
How to Cite
PRATONO, Dono et al.
EFEK TERAPI ADJUVAN METFORMIN PADA KANKER KOLOREKTAL.
Medika Kartika : Jurnal Kedokteran dan Kesehatan, [S.l.], v. 7, n. 4, p. 410-419, dec. 2024.
ISSN 2655-6537.
Available at: <http://medikakartika.unjani.ac.id/medikakartika/index.php/mk/article/view/844>. Date accessed: 25 jan. 2025.
Section
Articles
